Articles related to CME

Following participation in this educational activity, hematologists/oncologists, nurses, pharmacists, cell therapy experts, and other HCPs actively involved in the care of patients with multiple myeloma should be better able to:

It is critical to understand pupil testing and disorders. The pupil evaluation provides information about the retina, optic nerve, chiasm, optic tract, midbrain, cranial nerves III and V, and the orbit with a single quick, objective test. Furthermore, almost all of the true emergent conditions we see in optometry can be detected by a pupil examination.

Lack of Concordance Between Radiologic and Pathologic Responses in Neoadjuvant ICI Treatment of Melanoma: How Do I Assess Radiologic Progression? After taking part in this CME activity, medical oncologists, surgeons, dermatologists, oncology nurses, oncology pharmacists, and other members of the interprofessional team who manage patients with melanoma should be better able to:

Hematologist-oncologists, hematology-oncology NP/PAs, hematology-oncology nurses, and pharmacists should be better able to use criteria for erythroid-stimulating agent (ESA) failure to hasten the identification of patients with lower-risk myelodysplastic syndrome (MDS) refractory to ESA therapy, integrate safety and efficacy data on emerging therapeutic options into treatment planning for patients with lower-risk MDS after ESA failure, and integrate a multidisciplinary treatment approach after taking part in this CME activity.

Following completion of this CME activity, health-system and specialty pharmacists should be better able to review the transmissibility and clinical severity associated with SARS-CoV-2 variants, analyze the efficacy of vaccines and boosters for the prevention of infection and severe disease caused by SARS-CoV-2 variants, analyze the efficacy of oral antivirals and remdesivir in light of emerging SARS-CoV-2 variants, and discuss the efficacy of monoclonal antibodies and convalescent plasma for prevention and treatment in the clinical context of current and evolving SARS-CoV-2 variants.

After watching or listening to this CME activity hosted by Cynthia Matossian, MD, FACS, Founder and Medical Director at Matossian Eye Associates in Hopewell, NJ, and Jillian Ziemanski, OD, PhD, FAAO, Clinical Assistant Professor at the UAB School of Optometry at the University of Alabama at Birmingham, ophthalmologists and optometrists should be better equipped to analyze clinical trial data supporting the safety and effectiveness of device therapy to treat meibomian gland dysfunction (MGD).